Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.

Last reviewed: 19 November 2025

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance